Treatment with ferric carboxymaltose significantly improved left ventricular ejection fraction by 4.22% compared to -0.23% with standard of care in patients with HFrEF and iron deficiency.
Does intravenous ferric carboxymaltose improve cardiac function and structure in patients with heart failure with reduced ejection fraction and iron deficiency?
Iron deficiency negatively impacts cardiac energetics and structure in HFrEF, and intravenous ferric carboxymaltose improves cardiac performance, reverse remodelling, and clinical outcomes.
Absolute Event Rate: 4.22% vs -0.23%
p-value: p=<0.001
Over the past decade, the detrimental impact of iron deficiency in heart failure with reduced ejection fraction has become abundantly clear, showing a negative impact on functional status, quality of life, cardiac function and structure, exercise capacity and an increased risk of hospitalisation due to heart failure. Mechanistic studies have shown the impact of iron deficiency in altering mitochondrial function and negatively affecting the already altered cardiac energetics in heart failure with reduced ejection fraction. Such failing energetics form the basis of the alterations to cellular myocyte shortening, culminating in reduced systolic function and cardiac performance. The IRON-CRT trials show that ferric carboxymaltose is capable of improving cardiac structure and cardiac performance. This article discusses the effect of iron deficiency on cardiac function and structure and how it can be alleviated.
Pieter Martens (Wed,) conducted a review in Heart failure with reduced ejection fraction (HFrEF) and iron deficiency. Ferric carboxymaltose vs. Standard of care / Placebo was evaluated on Least square mean change in left ventricular ejection fraction (LVEF) from baseline to 3 months (p=<0.001). Treatment with ferric carboxymaltose significantly improved left ventricular ejection fraction by 4.22% compared to -0.23% with standard of care in patients with HFrEF and iron deficiency.